Nurix Therapeutics (NRIX) Other Non-Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Other Non-Current Assets data on file, last reported at $7.4 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $7.4 million, up 722.86% year-over-year; the trailing twelve-month figure through Feb 2026 was $7.4 million (up 722.86% YoY), and the FY2025 annual result was $968000.0, down 69.36% from the prior year.
• Other Non-Current Assets climbed to $7.4 million in Q1 2026 per NRIX's latest filing, from $968000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $7.4 million in Q1 2026 and troughed at $901000.0 in Q1 2022.
• A 5-year average of $2.1 million and a median of $901000.0 in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Assets tumbled 72.65% in 2022, then surged 722.86% in 2026.
• A 5-year view of Other Non-Current Assets shows it stood at $901000.0 in 2022, then changed by 0.0% to $901000.0 in 2023, then jumped by 250.61% to $3.2 million in 2024, then slumped by 69.36% to $968000.0 in 2025, then jumped by 665.91% to $7.4 million in 2026.
• Business Quant data shows NRIX's Other Non-Current Assets at $7.4 million in Q1 2026, $968000.0 in Q4 2025, and $7.4 million in Q3 2025.